Lymphoma Clinical Studies

Some of the many Cancer and Blood Disorders research opportunities available related to lymphoma are listed below. Select a study to review a brief description and requirements. Parents or guardians of children who might be eligible are encouraged to inquire about enrollment. Contact information is provided at the end of each study.

Please note that Pilot and Phase I studies are the most experimental and should be considered only after other treatments or trials have been attempted without success.

Thank you for exploring these opportunities and helping us to find cures and prevent childhood disease.

Clinical Studies


Acute Lymphoblastic Leukemia and Localized Lymphoblastic Lymphoma Treatment with Blinatumomab as part of Chemotherapy – Phase III

AALL1731: A Study to Compare the Addition of Blinatumomab in Combination with Chemotherapy in Patients Diagnosed with Standard-risk B-cell Acute Lymphoblastic Leukemia, and the Treatment of Patients with Localized B-cell Lymphoblastic Lymphoma

Read more

Children’s Oncology Group Long-Term Follow-up of Study Participants

ALTE05N1: Umbrella Long-Term Follow-Up Protocol for Participants with and without a History of Cancer

Read more

Children’s Oncology Group’s Project: EveryChild

APEC14B1: Project:Every Child, A Registry, Eligibility Screening, Biology and Outcome Study

Read more

Fitness Program for Adolescent and Young Adult Childhood Cancer Survivors: The StepByStep Study – Phase III

ALTE2031: StepByStep: A Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors

Read more

Fitness Program for Children and Adolescents Following Cancer Therapy – Phase III

ALTE1631: A Web-based Physical Activity Intervention among Children and Adolescents

Read more

M0 Medulloblastoma Treatment in Very Young Children – Phase I

ADVL1314: Study of Eribulin Mesylate, a Novel Microtubule Targeting Chemotherapeutic Agent, in Children with Refractory or Recurrent Solid Tumors including Lymphomas

Read more

Solid Tumor and Lymphoma Treatment with PI3K – Phase I/II

ADVL1721: Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Lymphoma

Read more

Solid Tumor Treatment with MLN4924, Temozolomide & Irinotecan

ADVL1615: Study of Pevonedistat (MLN4924), a NEDD8-Activating Enzyme Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Read more